187 related articles for article (PubMed ID: 26960538)
1. Safety of gadobutrol in over 23,000 patients: the GARDIAN study, a global multicentre, prospective, non-interventional study.
Prince MR; Lee HG; Lee CH; Youn SW; Lee IH; Yoon W; Yang B; Wang H; Wang J; Shih TT; Huang GS; Lirng JF; Palkowitsch P;
Eur Radiol; 2017 Jan; 27(1):286-295. PubMed ID: 26960538
[TBL] [Abstract][Full Text] [Related]
2. Safety of gadobutrol in more than 1,000 pediatric patients: subanalysis of the GARDIAN study, a global multicenter prospective non-interventional study.
Glutig K; Bhargava R; Hahn G; Hirsch W; Kunze C; Mentzel HJ; Schaefer JF; Willinek W; Palkowitsch P;
Pediatr Radiol; 2016 Aug; 46(9):1317-23. PubMed ID: 27041276
[TBL] [Abstract][Full Text] [Related]
3. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
Voth M; Rosenberg M; Breuer J
Invest Radiol; 2011 Nov; 46(11):663-71. PubMed ID: 21623211
[TBL] [Abstract][Full Text] [Related]
4. Post-marketing surveillance of gadobutrol for contrast-enhanced magnetic resonance imaging in Japan.
Tsushima Y; Awai K; Shinoda G; Miyoshi H; Chosa M; Sunaya T; Endrikat J
Jpn J Radiol; 2018 Nov; 36(11):676-685. PubMed ID: 30232584
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Safety of Macrocyclic Gadobutrol in Children Aged Younger Than 2 Years Including Term Newborns in Comparison to Older Populations.
Kunze C; Mentzel HJ; Krishnamurthy R; Fleck R; Stenzel M; Bhargava R; Burrowes D; Sutter G; Schultze-Mosgau M; Santiuste M; Hahn G
Invest Radiol; 2016 Jan; 51(1):50-7. PubMed ID: 26340504
[TBL] [Abstract][Full Text] [Related]
6. Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material.
Balzer JO; Loewe C; Davis K; Goyen M; Leiner T; Meaney JF; Pöckler-Schöniger C; Schulte-Altedorneburg G; Tombach B; Vosshenrich R; Wegener R
Eur Radiol; 2003 Sep; 13(9):2067-74. PubMed ID: 12928957
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients.
Hahn G; Sorge I; Gruhn B; Glutig K; Hirsch W; Bhargava R; Furtner J; Born M; Schröder C; Ahlström H; Kaiser S; Moritz JD; Kunze CW; Shroff M; Stokland E; Trnkova ZJ; Schultze-Mosgau M; Reif S; Bacher-Stier C; Mentzel HJ
Invest Radiol; 2009 Dec; 44(12):776-83. PubMed ID: 19858730
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of gadobutrol-enhanced MRA of the renal arteries: Results from GRAMS (Gadobutrol-enhanced renal artery MRA study), a prospective, intraindividual multicenter phase 3 blinded study.
Fabrega-Foster KE; Agarwal S; Rastegar N; Haverstock D; Agris JM; Kamel IR
J Magn Reson Imaging; 2018 Feb; 47(2):572-581. PubMed ID: 28574637
[TBL] [Abstract][Full Text] [Related]
9. Gadobutrol for contrast-enhanced magnetic resonance imaging in elderly patients: review of the safety profile from clinical trial, post-marketing surveillance, and pharmacovigilance data.
Endrikat J; Schwenke C; Prince MR
Clin Radiol; 2015 Jul; 70(7):743-51. PubMed ID: 25933719
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
[TBL] [Abstract][Full Text] [Related]
11. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.
Soyer P; Dohan A; Patkar D; Gottschalk A
J Magn Reson Imaging; 2017 Apr; 45(4):988-997. PubMed ID: 27726239
[TBL] [Abstract][Full Text] [Related]
12. Safety of Gadobutrol: Results From 42 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million Applications.
Endrikat J; Vogtlaender K; Dohanish S; Balzer T; Breuer J
Invest Radiol; 2016 Sep; 51(9):537-43. PubMed ID: 26964075
[TBL] [Abstract][Full Text] [Related]
13. Safety of gadobutrol: results of a non-interventional study of 3710 patients, including 404 children.
Glutig K; Hahn G; Kuvvetli P; Endrikat J
Acta Radiol; 2019 Jul; 60(7):873-879. PubMed ID: 30253660
[TBL] [Abstract][Full Text] [Related]
14. [Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study].
Vogl TJ; Friebe CE; Balzer T; Mack MG; Steiner S; Schedel H; Pegios W; Lanksch W; Banzer D; Felix R
Radiologe; 1995 Aug; 35(8):508-16. PubMed ID: 7568795
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.
Hammerstingl R; Adam G; Ayuso JR; Van Beers B; Belfiore G; Bellin MF; Bongartz G; Ernst O; Frericks B; Giuseppetti G; Heinz-Peer G; Laghi A; Martin J; Pering C; Reimer P; Richter GM; Roemer FW; Schäfer FK; Vilgrain V; Vogl TJ; Weishaupt D; Wall A; Zech CJ; Tombach B
Invest Radiol; 2009 Mar; 44(3):168-76. PubMed ID: 19169143
[TBL] [Abstract][Full Text] [Related]
16. Off-label intrathecal use of gadobutrol: safety study and comparison of administration protocols.
Halvorsen M; Edeklev CS; Fraser-Green J; Løvland G; Vatnehol SAS; Gjertsen Ø; Nedregaard B; Sletteberg R; Ringstad G; Eide PK
Neuroradiology; 2021 Jan; 63(1):51-61. PubMed ID: 32803338
[TBL] [Abstract][Full Text] [Related]
17. MR Angiography at 3 T of Peripheral Arterial Disease: A Randomized Prospective Comparison of Gadoterate Meglumine and Gadobutrol.
Loewe C; Arnaiz J; Krause D; Marti-Bonmati L; Haneder S; Kramer U;
AJR Am J Roentgenol; 2015 Jun; 204(6):1311-21. PubMed ID: 26001243
[TBL] [Abstract][Full Text] [Related]
18. Gadobutrol in the central nervous system at three doses: results from a phase II, randomized, multicenter trial.
Breuer J; Gutierrez J; Latchaw R; Lehr R; Sorensen AG
J Magn Reson Imaging; 2014 Feb; 39(2):410-8. PubMed ID: 23681501
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, randomized, controlled, single-blind comparison phase III study to determine the efficacy and safety of gadobutrol 1.0 M versus gadopentetate dimeglumine following single injection in patients referred for contrast-enhanced MRI of the body regions or extremities.
Kuwatsuru R; Takahashi S; Umeoka S; Sugihara R; Zeng M; Huan Y; Peng W; Ma L; Guo L; Teng G; Yao W; Tozaki M; Endo M; Kaji S; Ro T; Tae Hahn S; Chul Kang B; Nishimura H; Sugawara Y; Katakami N; Breuer J; Aitoku Y
J Magn Reson Imaging; 2015 Feb; 41(2):404-13. PubMed ID: 24692302
[TBL] [Abstract][Full Text] [Related]
20. Intraindividual quantitative and qualitative comparison of gadopentetate dimeglumine and gadobutrol in time-resolved contrast-enhanced 4-dimensional magnetic resonance angiography in minipigs.
Hadizadeh DR; Jost G; Pietsch H; Weibrecht M; Perkuhn M; Boschewitz JM; Keil VC; Träber F; Kukuk GM; Schild HH; Willinek WA
Invest Radiol; 2014 Jul; 49(7):457-64. PubMed ID: 24598442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
